Skip to content

MAZE MAZE Additional Paid-In Capital

Additional Paid-In Capital at other companies

Septerna, Inc. logo
Septerna, Inc.SEPN
$554.87M+2.8%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$942.7M+29.5%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
$1.13B+33.4%
Zymeworks logo
ZymeworksZYME
$107.53M-30.3%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$1.57B+23.2%
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
$821.9M

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B+201%
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's additional paid-in capital?
MAZE (MAZE) reported additional paid-in capital of $855.54M in Q1 2026.
How has MAZE's additional paid-in capital changed year-over-year?
MAZE's additional paid-in capital increased by 25.2% year-over-year, from $683.24M to $855.54M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.